Human Anti-ErbB2 Antibody CDR Optimization for Phosphorylation Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-ErbB2 antibodies are limited in their ability to specifically inhibit Heregulin-induced ErbB2 phosphorylation and cell proliferation in cancer cells, with existing treatments like Herceptin having limitations in efficacy and specificity.
Innovation Solution
Development of a human antibody or antigen binding fragment that specifically binds to human ErbB2, inhibiting Heregulin-induced ErbB2 phosphorylation with an EC50 of less than 50 ng/ml, utilizing specific heavy and light chain CDR sequences to target ErbB2 with high affinity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing anti-ErbB2 antibodies (e.g., Herceptin) are used, then some inhibition of ErbB2 phosphorylation is achieved, but the specificity and potency are insufficient with EC50 values not meeting the threshold of less than 50 ng/ml
Solution Approach 1:
The patent applies parameter changes by optimizing the antibody's binding parameters through specific CDR sequence selection. The heavy chain CDR1 (SEQ ID NO: 2), CDR2 (SEQ ID NO: 4), and CDR3 (SEQ ID NO: 6) sequences, combined with specific light chain CDR sequences, create an antibody with enhanced binding affinity and specificity to ErbB2, achieving EC50 values less than 50 ng/ml while maintaining high specificity for Heregulin-induced phosphorylation inhibition.
2Adaptability or versatility
If broader ErbB2 inhibition is achieved, then more cancer types may be treated, but specificity for Heregulin-induced phosphorylation may be reduced
Solution Approach 1:
The patent applies local quality by designing the antibody to target specific local regions (epitopes) on the ErbB2 receptor that are involved in Heregulin-induced phosphorylation. The specific CDR sequences are engineered to bind with high affinity to these critical regions, ensuring selective inhibition of Heregulin-induced signaling pathways while preserving the antibody's applicability across different ErbB2-overexpressing cancer types.
3Measurement precision
If antibody specificity is enhanced through specific CDR sequences, then potency increases, but the complexity of antibody design and production increases
Solution Approach 1:
The patent applies segmentation by dividing the antibody into its functional components - specifically identifying and optimizing the six CDR regions (three in heavy chain, three in light chain) that are responsible for antigen binding. This segmented approach allows for rational design of each CDR sequence to achieve the desired binding characteristics while streamlining the overall production process through modular construction of the antibody molecule.
Data Source
Figure 1
Figure 2
Figure 3A~3C
AI summary
The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to ErbB2, preferably human ErbB2. In another embodiment, the antibodies or antigen-binding portions thereof inhibit ErbB2. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins or portions thereof derived from human anti-ErbB2 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-ErbB2 antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.